Company intelligence / Profile preview

HardyPaw

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

HardyPaw is an early-stage biotechnology company dedicated to developing innovative therapeutic solutions for companion animals, specifically focusing on cats and dogs. The company leverages advancements in human medicine to create species-specific treatments for chronic conditions such as osteoarthritis pain and dermatological disorders. By focusing on high-unmet-need areas in veterinary medicine, HardyPaw aims to improve the quality of life and longevity of pets through targeted biologics and small molecule therapies. Their current research efforts are centered on translating proven molecular targets into safe and effective veterinary applications.

Therapeutic areas: NephrologyRheumatologyDermatology
Modalities: Small moleculeMonoclonal antibody
Industry: Veterinary

Beyond the preview

Go deeper on HardyPaw.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HardyPaw.

Explore the full profile